Beta-talasemi major komplikasyonu olarak gelişen diabetes mellitus ve hipoparatiroidi

Yıl 2014, Cilt: 24 Sayı: 4, 155 - 157, 01.01.2014

Ruhuşen Kutlu Mustafa Kulaksızoğlu Ayşe Özlem Kılıçaslan

Öz

Beta-talasemi major ilk defa Cooley ve Lee tarafından tanımlanmış olup, β-globin zincir sentezinde azalma ile giden, resesif karakterli bir hemoglobin bozukluğudur. Homozigot olgular düzenli kan transfüzyonu gerektiren ağır anemi ile seyreder. Şelasyon ve transfüz- yon tedavisi kombinasyonu yaşam beklentisini 40-50’li yaşlara kadar dramatik olarak uzatır. Diğer yandan sık kan transfüzyonları vücutta fazla demir birikimine yol açarak hipogonadizm, diabetes mellitus, hipotiroid, hipoparatiroid ve diğer endokrin bozukluklara neden olabilir. Bu yazıda talasemi major komplikasyonu olarak diabetes mellitus ve hipoparatiroidi gelişen bir olgu sunumu takdim edilmiştir

Anahtar Kelimeler

Beta-talasemi major, diabetes mellitus, hipoparatiroid

Diabetes mellitus and hypoparathyroidism developed as a complication of beta-thalassemia major

Öz

Beta-thalassemia major, first described by Cooley and Lee, is a recessively inherited hemoglobin disorder and characterized by redu- ced synthesis of β-globin chain. The homozygous state results in severe anemia, which needs regular blood transfusion. The combi- nation of transfusion and chelation therapy has dramatically extended the life expectancy of thalassemic patients who can recently survive into their fourth and fifth decades of life. On the other hand, frequent blood transfusion in turn can lead to iron overload whi- ch may result in hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism and other endocrine abnormalities. In this paper, a case with diabetes mellitus and hypoparathyroidism developing as complications of beta-thalassemia major was presented

Anahtar Kelimeler

Beta-thalassemia major, diabetes mellitus, hypoparathyroidism

Kaynakça

• Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al. Metabolic and endocrinologic complications in beta-thalassemia major: a multi- center study in Tehran. BMC Endocr Disord 2003;3:4.
• Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR. Diabe- tes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev 2004;2 Suppl 2:285- 91.
• Habeb AM, Al-Hawsawi ZM, Morsy MM, et al. Endocrinopathies in beta-thalassemia major. Prevalence, risk factors, and age at diag- nosis in Northwest Saudi Arabia. Saudi Med J 2013;34:67-73.
• Belhoul KM, Bakir ML, Saned MS, et al. Serum ferritin levels and endocrinopathy in medically treated patients with beta thalassemia major. Ann Hematol 2012;91:1107-14.
• Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and pre- valence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 2008;6 Suppl 1:158-69.
• Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complica- tions in patients with Thalassaemia Major. Pediatr Endocrinol Rev 2007;5:642-8.
• Canatan D, Arcasoy A, Öcal G ve ark. Multipl endokrin kompli- kasyonlari olan bir thalassemia major olgusu. Turkiye Klinikleri J Pediatr 1993;2:205-8.
• Sert A, Albayrak CU, Çalışkan Ü, Atabek ME. Konya’daki talasemi majorlü hastalarda bozulmuş glukoz toleransı ve diyabet prevalan- sı. Genel Tıp Derg 2009;19:1-8.
• Torres FA, Bonduel M, Sciuccati G, et al. Beta thalassemia major in Argentina. Medicina (B Aires) 2002;62:124-34.
• Cario H, Holl RW, Debatin KM, Kohne E. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemo- chromatosis: assessment by oral glucose tolerance test. Eur J Pedi- atr 2003;162:139-46.
• Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Comp- lications in Non-endocrine Diseases. Clin Endocrinol (Oxf) 1995;42:581-6.
• Baytan B, Sağlam H, Erdöl Ş ve ark. Talasemi majorlü vakalarda endokrin komplikasyonların değerlendirilmesi. Güncel Pediatri 2008;6:58-65.
• Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systema- tic review. Osteoporos Int 2010;21:183-7.